维奈托克与达雷妥尤单抗联合治疗在急性髓系白血病小鼠模型中显示出临床前疗效。
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia.
作者信息
Mistry Jayna J, Hellmich Charlotte, Lambert Amelia, Moore Jamie A, Jibril Aisha, Collins Angela, Bowles Kristian M, Rushworth Stuart A
机构信息
Norwich Medical School, University of East Anglia, Norwich Research Park, NR4 7UQ, Norwich, UK.
Earlham Institute, Norwich Research Park, NR4 7UH, Norwich, UK.
出版信息
Biomark Res. 2021 May 13;9(1):35. doi: 10.1186/s40364-021-00291-y.
Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.
尽管近期治疗方面取得了进展，但急性髓系白血病（AML）仍然是一种无法治愈的恶性肿瘤。最近出现了一些用于治疗AML的新疗法，这些疗法靶向BCL-2或膜受体CD38。在此，我们表明，维奈托克（Venetoclax）和达雷妥尤单抗（Daratumumab）联合治疗在体外和体内均导致肿瘤进展较慢且白血病生长减少。这些数据为维奈托克和达雷妥尤单抗联合治疗AML的临床评估提供了证据。
Zotero 插件